ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc (RIGL)

10.59
0.61
(6.11%)
Closed July 15 4:00PM
10.59
0.00
( 0.00% )
Pre Market: 4:00AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
10.59
Bid
9.26
Ask
11.00
Volume
-
0.00 Day's Range 0.00
0.712 52 Week Range 10.8886
Market Cap
Previous Close
10.59
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
1,393,089
Shares Outstanding
17,558,294
Dividend Yield
-
PE Ratio
-7.41
Earnings Per Share (EPS)
-1.43
Revenue
116.88M
Net Profit
-25.09M

About Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Ri... Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Rigel Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RIGL. The last closing price for Rigel Pharmaceuticals was $10.59. Over the last year, Rigel Pharmaceuticals shares have traded in a share price range of $ 0.712 to $ 10.8886.

Rigel Pharmaceuticals currently has 17,558,294 shares outstanding. The market capitalization of Rigel Pharmaceuticals is $185.94 million. Rigel Pharmaceuticals has a price to earnings ratio (PE ratio) of -7.41.

RIGL Latest News

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., July 12, 2024 SOUTH SAN FRANCISCO, Calif., July 12, 2024 /PRNewswire/ -- Rigel...

Rigel Announces Reverse Stock Split

Rigel Announces Reverse Stock Split PR Newswire SOUTH SAN FRANCISCO, Calif., June 25, 2024 SOUTH SAN FRANCISCO, Calif., June 25, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL...

Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application

Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application PR Newswire SOUTH SAN FRANCISCO, Calif., June 24, 2024 GAVRETO will be available from Rigel in the U.S...

Rigel Announces Five Presentations at the EHA2024 Hybrid Congress

Rigel Announces Five Presentations at the EHA2024 Hybrid Congress PR Newswire SOUTH SAN FRANCISCO, Calif., June 14, 2024 -     Oral presentation highlighting final five-year efficacy data from...

Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting

Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting PR Newswire SOUTH SAN FRANCISCO, Calif., June 3, 2024 -       Long-term efficacy data from the...

Rigel to Present at the Jefferies Global Healthcare Conference

Rigel to Present at the Jefferies Global Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif., May 30, 2024 SOUTH SAN FRANCISCO, Calif., May 30, 2024 /PRNewswire/ -- Rigel...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
12.7334.73282442757.8610.677.71429699.54746168CS
49.64971026.236307560.940310.88860.7715461201.8161665CS
129.46837.1681415931.1310.88860.7713930891.28508454CS
269.26696.2406015041.3310.88860.7713479991.30664656CS
529.32733.8582677171.2710.88860.71212219941.21488949CS
1566.44155.1807228924.1510.88860.6423670151.57969827CS
2608.09323.62.510.88860.6425617902.28444474CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CDTConduit Pharmaceuticals Inc
$ 0.4588
(91.17%)
19.75M
WNWMeiwu Technology Company Ltd
$ 1.245
(39.89%)
2.2M
SYRASyra Health Corporation
$ 1.75
(31.09%)
1
WINTWindtree Therapeutics Inc
$ 4.50
(21.62%)
10
TPCSTechPrecision Corporation
$ 4.36
(17.18%)
1
AMIXAutonomix Medical Inc
$ 1.13
(-18.12%)
412.36k
GRNQGreenpro Capital Corporation
$ 0.9665
(-18.09%)
80.61k
AREBAmerican Rebel Holdings Inc
$ 0.5699
(-15.32%)
141.53k
TANHTantech Holdings Ltd
$ 0.5187
(-15.12%)
1.08M
CYNCYNGN Inc
$ 7.82
(-14.81%)
11.58k
CDTConduit Pharmaceuticals Inc
$ 0.4573
(90.54%)
20.32M
KRKR36Kr Holdings Inc
$ 0.3125
(5.15%)
4.57M
SLNASelina Hospitality PLC
$ 0.0662
(5.75%)
2.45M
WNWMeiwu Technology Company Ltd
$ 1.23
(38.20%)
2.22M
MAXNMaxeon Solar Technologies Ltd
$ 0.2211
(-2.60%)
1.46M

RIGL Discussion

View Posts
dcaf7 dcaf7 3 months ago
Titles of olutasidenib presentations at ASCO:
1. Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia.
2. Patients with relapsed/refractory mIDH1 AML who proceeded to transplant after olutasidenib treatment.
3. Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.
👍️0
Monksdream Monksdream 3 months ago
RIGL under $2
👍️0
Monksdream Monksdream 4 months ago
RIGL under $2
👍️0
dcaf7 dcaf7 4 months ago
Just published, "Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)". The results of this phase 2 study support data from registrational cohort demonstrating that Olutasidenib works well in patients previously treated with venetoclax.
https://pubmed.ncbi.nlm.nih.gov/38538632/
👍️0
dcaf7 dcaf7 4 months ago
Good read on Olutasidenib
https://journals.lww.com/oncology-times/fulltext/2024/03000/olutasidenib_as_a_breakthrough_for_r_r_midh1_aml.25.aspx
Important further research: 1) studying whether olutasidenib can eliminate the stem cell fraction within each patient's IDH1-mutant AML; 2) characterization of synthetic lethality involving olutasidenib in IDH1-mutant AML.
👍️0
dcaf7 dcaf7 5 months ago
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
FEBRUARY 22, 2024 7:50AM EST
GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer
Acquisition of established U.S. marketed product further expands Rigel's portfolio and leverages Rigel's existing infrastructure in both the institutional and community settings
GAVRETO generated ~$28M in U.S. net product sales in 2023
👍️0
bme bme 11 months ago
Rigl should be VTGN (Today) one day.
👍️0
bme bme 12 months ago
Yeah. Should be good Q.
👍️0
TucsonPhil TucsonPhil 1 year ago
Hopefully, the inducement grants are being used to hire qualified talent, rather than pad the wallets of friends and relatives.
👍️0
bme bme 1 year ago
Better be good.
👍️0
bme bme 1 year ago
Ugly.
👍️0
The Night Stalker The Night Stalker 1 year ago
nice
👍️0
The Night Stalker The Night Stalker 1 year ago
nice
👍️0
The Night Stalker The Night Stalker 1 year ago
base
👍️0
bme bme 1 year ago
What a shoot! Amazing.
👍️0
bme bme 1 year ago
The next quarter fin should include the rev for TAVALISSE. "In April, Rigel's partner Kissei announced the launch of TAVALISSE in Japan for the treatment of chronic ITP."
1. What else should we expect as for the rev?
2. Result of phase 3 of Fostamatinib3 COVID 19?
3. Status of Fostamatinib-ACTIV4 COVID 19?
4. Partnered Programs?
👍️0
The Night Stalker The Night Stalker 1 year ago
nice fins
👍️0
The Night Stalker The Night Stalker 1 year ago
gem
👍️0
The Night Stalker The Night Stalker 1 year ago
gem
👍️0
The Night Stalker The Night Stalker 1 year ago
easy
👍️0
bme bme 1 year ago
Nice spike AH today.
👍️0
bme bme 1 year ago
Higher low higher low.... next leg is North.
👍️0
The Night Stalker The Night Stalker 1 year ago
https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
👍️0
The Night Stalker The Night Stalker 1 year ago
https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
👍️0
bme bme 1 year ago
acting wild atm, but still healthy.
👍️0
The Night Stalker The Night Stalker 1 year ago
nice
👍️0
bme bme 1 year ago
Nice & Healthy.
👍️0
The Night Stalker The Night Stalker 1 year ago
quite the dip
👍️0
The Night Stalker The Night Stalker 1 year ago
ready
👍️0
The Night Stalker The Night Stalker 1 year ago
ready
👍️0
The Night Stalker The Night Stalker 1 year ago
red to green
👍️0
The Night Stalker The Night Stalker 1 year ago
red to green
👍️0
bme bme 1 year ago
Wonderful!
👍️0
The Night Stalker The Night Stalker 1 year ago
beauty
👍️0
The Night Stalker The Night Stalker 1 year ago
nice
👍️0
bme bme 1 year ago
Expect Q4 filing this week?
👍️0
bme bme 1 year ago
Be seeing that. Lot of 1.95 transactions so far
👍️0
TucsonPhil TucsonPhil 1 year ago
Revenue potential appears good. SP is slowly rising, and looks like it has been in accumulation for the past few weeks.
👍️0
bme bme 2 years ago
SP should be a lot higher since the Q4 revenue is more than double from last year...
👍️0
Welldoctor Welldoctor 2 years ago
Apparently insider buying reported on ST. Take it for what it’s worth.
👍️0
Welldoctor Welldoctor 2 years ago
RIGL news out
👍️0
bme bme 2 years ago
Looks like it will poke thru & bye bye 1 today.
👍️0
doesitreallymatter doesitreallymatter 2 years ago
Just like ABQQ. Right?
👍️0
subslover subslover 2 years ago
You are 1/2 way there!!!!
👍️0
KngmAz KngmAz 2 years ago
Wow - BOOM - we just went over a dollar - next step $10.00 - DON'T MISS OUT!!
👍️0
KngmAz KngmAz 2 years ago
This is a $10.00 per share stock in the very near future - EASILY!!
👍️0
Alaska40 Alaska40 2 years ago
I just bought in. Seems like a good run could come in the near future.
👍️0
subslover subslover 2 years ago
Consolidating nicely on Continuation from last week!
👍️0
bcapps66 bcapps66 2 years ago
LOL!
👍️0
THEMASTERS_SON THEMASTERS_SON 2 years ago
GIVE ME MY $2DOLLAS…YA BUM
👍️0

Your Recent History

Delayed Upgrade Clock